Clinical trials: Multiple Sclerosis (Relapsing Remitting)
Multiple Sclerosis, Relapsing-Remitting
Treatment of Multiple Sclerosis Using Over the Counter Inosine
The purpose of this study is to determine whether raising low levels of the natural antioxidant uric acid by the administration of a precursor, inosine, has any therapeutic effect on the progression of Relapsing Remitting…
- Trial name
- NCT00067327
- Testing
- Inosine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Relapsing-Remitting Multiple Sclerosis
Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis
The aim of the study is to determine whether a therapeutic strategy combining mitoxantrone and interferon beta1b can delay disease progression of at least one point on EDSS scale in patients with clinically very active…
- Trial name
- NCT00219908
- Testing
- Mitoxantrone
- Where
- 23 sites in France, Italy
- Volunteers
- 124 people
- Sponsor
- Rennes University Hospital
Relapsing Remitting Multiple Sclerosis
A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis
The purpose of this study is to determine if using Avonex in combination with Zocor is a safe and effective therapy for subjects with relapsing remitting multiple sclerosis.
- Trial name
- NCT00242268
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alabama Neurology Associates, PC
Multiple Sclerosis
A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis
This is a clinical trial in relapsing-remitting Multiple Sclerosis to determine if Topamax added to Avonex has a neuroprotective effect as measured by the brain parenchymal fraction ( a measure of brain shrinkage) and by clinical…
- Trial name
- NCT00217295
- Testing
- Avonex and Topamax
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Multiple Sclerosis Institute